ProCE Banner Activity

What I Want My Colleagues to Know About Ki67 in HR-Positive/HER2-Negative Early Breast Cancer

PDF
Clinical Thought
Are you testing for Ki67 expression levels in patients with early-stage hormone receptor-positive/HER2-negative breast cancer? Read this commentary for a pathologist’s perspective on Ki67 testing.

Released: December 28, 2021

Expiration: December 27, 2022

Share

Faculty

Sunil Badve

Sunil Badve, MD, FRCPath

Provided by

Provided by a partnership between the American Society for Clinical Pathology and Clinical Care Options, LLC.
ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sunil Badve, MD, FRCPath